title: The pathobiologic implications for treatment. Old and new strategies in the treatment of chronic asthma.
abstract: An increased understanding of the pathobiology of asthma has led to improved treatment for chronic asthma. This article discusses the old and new strategies of asthma therapy based on a pathobiologic approach. Therapeutic agents discussed include beta-adrenergic agonists, methylxanthines, corticosteroids, cromolyn, nedocromil, leukotriene modifiers, and new investigational agents.
authors.affiliation: Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
authors.forename: T
authors.initials: T
authors.lastname: Horiuchi
authors.forename: M
authors.initials: M
authors.lastname: Castro
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004361:Drug Tolerance; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D058915:Purinergic P1 Receptor Antagonists; D000068299:Salmeterol Xinafoate; D014970:Xanthines / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D020024:Leukotriene Antagonists; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; C008514:methylxanthine; D000068299:Salmeterol Xinafoate; D004205:Cromolyn Sodium; D000420:Albuterol